MYIG Stock Overview
A biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Mydecine Innovations Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.018 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 2.77 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -79.41% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYIG | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | 1.7% |
| 1Y | -79.4% | 2.0% | 9.0% |
Return vs Industry: MYIG underperformed the UK Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: MYIG underperformed the UK Market which returned 9% over the past year.
Price Volatility
| MYIG volatility | |
|---|---|
| MYIG Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine MYIG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 3 | Josh Bartch | www.mydecine.com |
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005.
Mydecine Innovations Group Inc. Fundamentals Summary
| MYIG fundamental statistics | |
|---|---|
| Market cap | UK£262.65k |
| Earnings (TTM) | -UK£7.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs MYIG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYIG income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$12.46m |
| Earnings | -CA$12.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -37.4% |
How did MYIG perform over the long term?
See historical performance and comparison